EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Resectability stages of pancreatic cancer: nationwide reference

Thomas F Stoop iD, Ingmar F Rompen, Mahsoem Ali iD, Bas Groot Koerkamp iD, Bert A Bonsing, Jan Willem B de Groot, Geert A Cirkel, Hjalmar C van Santvoort, Inez M Verpalen, I Quintus Molenaar, Johanna W Wilmink, Judith de Vos-Geelen iD und 9 weitere

British Journal of Surgery · 03.07.2025 · 112 (7)

DOI: 10.1093/bjs/znaf120 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, online erschienen am 11.07.2025. Verfasst von Thomas F Stoop und 20 weiteren Autor:innen. Beteiligte Einrichtung: Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 5 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Dutch Cancer Society, Deltaplan Alvleesklierkanker for the Dutch PREOPANC-4 trial on multidisciplinary management of LAPC, Cultuurfonds.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

At diagnosis, pancreatic adenocarcinoma is categorized into resectability stages based on extent of vascular involvement and presence of metastases at cross-sectional imaging1,2. However, reliable population-based data regarding the distribution of these stages is lacking. This influences our perspective on this disease. In current literature, the rates of the National Comprehensive Cancer Network (NCCN) resectability criteria (that is primary resectable (PRPC), borderline resectable (BRPC), locally advanced (LAPC), and metastatic (MPC) pancreatic cancer) are based on inadequate conversion of the AJCC TNM classification3,4. The current study determined the distribution of NCCN pancreatic adenocarcinoma resectability stages among all-comers using the nationwide cancer registry. This study followed the STROBE guideline. The protocol was approved by the scientific committee of the Dutch Pancreatic Cancer Group. The Netherlands Cancer Registry (NCR) was used to identify and include consecutive Dutch residents diagnosed with either clinically suspected or pathology-proven pancreatic adenocarcinoma, regardless of subsequent treatment (2017–2022). In the NCR presence of distant metastases and vascular involvement is based on local radiology reports of cross-sectional imaging at diagnosis. In addition, the AJCC cTNM staging is enriched by the NCR with findings during non-therapeutic surgery (that is staging laparoscopy, laparotomy). Extent of portomesenteric vein and major peri-pancreatic arteries (that is superior mesenteric artery, coeliac axis, common hepatic artery, proper hepatic artery) involvement on imaging is registered in quartiles of 90°. The following definitions were used to reflect the 2024 NCCN categorization of resectability4: PRPC: no arterial involvement and ≤180° portomesenteric venous involvement; BRPC: ≤180° arterial involvement and/or ≤270° portomesenteric venous involvement; LAPC:>180° arterial involvement and/or >270° portomesenteric venous involvement. Missing data on vascular involvement and cTNM stage were handled with multiple imputation by chained equations and predictive mean matching (30 imputations, 20 iterations), under the missing-at-random assumption, using clinical parameters (that is age, WHO performance status), radiological disease characteristics (that is tumour size, cT and cN stage, tumour location, arterial and venous tumour involvement), and advice on curative treatment. R statistical software (version 4.4.2, mice package) was used for imputation. Among 16 412 patients diagnosed with pancreatic adenocarcinoma, the distribution of patients with PRPC, BRPC, LAPC, and MPC was 23.4%, 8.2%, 10.9%, and 57.5% respectively (Table 1). Details from patients with non-metastatic disease are presented in Table S1. These respective rates of disease stage differed between primary tumour locations in pancreatic head (31.4%, 10.8%, 12.7%, 45.1%) versus pancreatic body (10.0%, 5.5, 13.2%, 71.3%) versus pancreatic tail (11.1%, 2.0%, 3.5%, 83.4%) (P < 0.001). Patients with pancreatic adenocarcinoma—staging and resectability at diagnosis All measures are the number of patients with the percentage between brackets. Imputed data on 1460 patients (8.9%) for NCCN resectability stage, 1466 patients (8.9%) for AJCC cTNM staging, and 1926 patients (11.7%) for tumour location. *Before data imputation of the 1460 patients with missing data on NCCN resectability stage, the rates of PRPC, BRPC, LAPC, and metastatic disease were 21.7% (n = 3251), 6.2% (n = 928), 8.9% (n = 1331), and 63.1% (n = 9442). Patients with pancreatic adenocarcinoma—staging and resectability at diagnosis All measures are the number of patients with the percentage between brackets. Imputed data on 1460 patients (8.9%) for NCCN resectability stage, 1466 patients (8.9%) for AJCC cTNM staging, and 1926 patients (11.7%) for tumour location. *Before data imputation of the 1460 patients with missing data on NCCN resectability stage, the rates of PRPC, BRPC, LAPC, and metastatic disease were 21.7% (n = 3251), 6.2% (n = 928), 8.9% (n = 1331), and 63.1% (n = 9442). This population-based study on the NCCN resectability stages of pancreatic adenocarcinoma indicates that the rate of LAPC was lower than reported in literature (11% versus 30–35% respectively)1, whereas the rate of PRPC is higher (23% versus 10–15% respectively)1. These considerable differences are most likely caused by publication, selection, and referral bias and different definitions. These findings should be interpreted considering some limitations. First, staging was based on the local radiology report, central review of imaging was not feasible, and details of cross-sectional imaging modalities and scan protocols were not recorded. This could have impacted distribution among resectability categories5. Second, information on possible combinations of involved arteries and portomesenteric venous reconstructability was lacking, which may have somewhat influenced the rates of BRPC and LAPC. The main strength is that this is the first study based on a nationwide registry that reports the distribution of the anatomical resectability stages among all-comers with pancreatic adenocarcinoma and may serve as a reference for future literature and study design. Tessa E. Hendriks (Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands); Jeanin E. van Hooft (Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands); Maarten F. Bijlsma (Amsterdam UMC, location University of Amsterdam, Center for Experimental and Molecular Medicine, Laboratory of Experimental Oncology and Radiobiology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands); Miriam L. Wumkes (Department of Medical Oncology, Jeroen Bosch Hospital, ‘s Hertogenbosch, The Netherlands); Arantza Fariña (Amsterdam UMC, location University of Amsterdam, Department of Pathology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands); Lieke Brouwer-Hol (Department of Gastroenterology & Hepatology, Maasstad Ziekenhuis, Rotterdam, The Netherlands); Casper H.J. van Eijck (Department of Surgery and Pulmonology, Erasmus MC Cancer Institute, University Medical Center, Rotterdam, The Netherlands); Rogier P. Voermans (Amsterdam Gastroenterology Endocrinology Metabolism, Amsterdam, The Netherlands; Amsterdam UMC, location University of Amsterdam, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands); Ignace H. de Hingh (Department of Surgery, Catharina Hospital, Eindhoven, The Netherlands); Ellen Hendriksen (Department of Radiation Oncology, Medisch Spectrum Twente, Enschede, The Netherlands); Hanneke W.M. van Laarhoven (Amsterdam UMC, location University of Amsterdam, Department of Medical Oncology, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands); Laura C. Leeuwenburgh (Amsterdam UMC, location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands) Thomas F. Stoop receives grants from KWF Dutch Cancer Society (#2021-2/14106) and Deltaplan Alvleesklierkanker (#2022-3/WOO 2102) for the Dutch PREOPANC-4 trial on multidisciplinary management of locally advanced pancreatic cancer (NCT05524090). He also receives grants from the Cultuurfonds (Jan de Ruijsscher/Pia Huisman Fonds) and Cancer Center Amsterdam; all outside this submitted work. Ingmar F. Rompen is supported by the Swiss National Science Foundation (SNSF, grant number 217684); all outside this submitted work. Marc G. Besselink has been rewarded by KWF Dutch Cancer Society (#2021-2/14106) and Deltaplan Alvleesklierkanker (#2022-3/WOO 2102) for the Dutch PREOPANC-4 trial on multidisciplinary management of locally advanced pancreatic cancer (NCT05524090); by Intuitive Surgical for the DIPLOMA-2 trial on minimally invasive pancreatoduodenectomy (ISRCTN27483786); by Ethicon and Intuitive for the European quality registry on minimally invasive pancreatic surgery; and by Intuitive for the European LEARNBOT training program for robot-assisted pancreatoduodenectomy; all outside this submitted work. Judith de Vos-Geelen has served as a consultant for Amgen, AstraZeneca, Merck Sharp and Dohme (MSD), Pierre Fabre, and Servier, and has received research funding from Servier; all outside this submitted work. Johanna W. Wilmink has served as a consultant for AstraZeneca, Merck Sharp and Dohme (MSD), and Servier, and has received research funding from Servier, Merck Sharp and Dohme (MSD) and Nordic; all outside this submitted work. Martijn W.J. Stommel has been rewarded by the Rising Tide Foundation for the Dutch REMBRANDT trial on the effectiveness of Braun anastomosis in reducing delayed gastric emptying after open pancreatoduodenectomy (NCT05709197); all outside this submitted work. Thomas F. Stoop (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Writing—original draft), Ingmar F. Rompen (Conceptualization, Formal analysis, Investigation, Methodology, Writing—review & editing), Mahsoem Ali (Formal analysis, Investigation, Methodology, Writing—review & editing), Bas Groot Koerkamp (Conceptualization, Writing—review & editing), Bert A. Bonsing (Conceptualization, Writing—review & editing), Jan-Willem B. de Groot (Conceptualization, Writing—review & editing), Geert A. Cirkel (Conceptualization, Writing—review & editing), Hjalmar C. van Santvoort (Conceptualization, Writing—review & editing), Inez M. Verpalen (Conceptualization, Writing—review & editing), I. Quintus Molenaar (Conceptualization, Writing—review & editing), Johanna W. Wilmink (Conceptualization, Writing—review & editing), Judith de Vos-Geelen (Conceptualization, Writing—review & editing), Lois A. Daamen (Conceptualization, Writing—review & editing), Marc R.W. Engelbrecht (Conceptualization, Writing—review & editing), Marjolein Y.V. Homs (Conceptualization, Writing—review & editing), Martijn P.W. Intven (Conceptualization, Writing—review & editing), Martijn W.J. Stommel (Conceptualization, Writing—review & editing), Vincent E. de Meijer (Conceptualization, Writing—review & editing), Lydia G. van der Geest (Conceptualization, Data curation, Funding acquisition, Methodology, Resources, Supervision, Writing—original draft, Writing—review & editing), and Marc G. Besselink (Conceptualization, Investigation, Methodology, Supervision, Writing—review & editing) The authors declare no conflict of interest. Supplementary material is available at BJS online. The data that support the findings of our study are available from the corresponding author upon reasonable request.

Autor:innen und Institutionen

  • Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Amsterdam, The Netherlands.
  • Department of General, Visceral, and Transplantation Surgery, Heidelberg University Hospital, Heidelberg, Germany.
  • Department of Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.
  • Department of Medical Oncology, Isala Oncology Center, Zwolle, The Netherlands.

ORCID-Profile: Thomas F Stoop, Mahsoem Ali, Bas Groot Koerkamp, Judith de Vos-Geelen, Lois A Daamen, Martijn W J Stommel, Vincent E de Meijer, Lydia G van der Geest, Marc G Besselink

Förderung

  • Dutch Cancer Society
  • Deltaplan Alvleesklierkanker for the Dutch PREOPANC-4 trial on multidisciplinary management of LAPC
  • Cultuurfonds
  • Cancer Center Amsterdam
  • Swiss National Science Foundation
  • Intuitive Surgical for the DIPLOMA-2 trial on minimally invasive pancreatoduodenectomy
  • Ethicon and Intuitive for the European quality registry on minimally invasive pancreatic
  • surgery

Zitieren

APA

Stoop, T. F., Rompen, I. F., Ali, M., Groot Koerkamp, B., Bonsing, B. A., de Groot, J. W. B., Cirkel, G. A., van Santvoort, H. C., Verpalen, I. M., Molenaar, I. Q., Wilmink, J. W., de Vos-Geelen, J., Daamen, L. A., Engelbrecht, M. R. W., Homs, M. Y. V., Intven, M. P. W., Stommel, M. W. J., de Meijer, V. E., van der Geest, L. G., …, & Dutch Pancreatic Cancer Group (2025). Resectability stages of pancreatic cancer: nationwide reference. British Journal of Surgery, 112(7). https://doi.org/10.1093/bjs/znaf120

Vancouver

Stoop TF, Rompen IF, Ali M, Groot Koerkamp B, Bonsing BA, de Groot JWB, et al. Resectability stages of pancreatic cancer: nationwide reference. British Journal of Surgery. 2025;112(7). doi:10.1093/bjs/znaf120

BibTeX
@article{Stoop2025,
  author = {Stoop, Thomas F and Rompen, Ingmar F and Ali, Mahsoem and Groot Koerkamp, Bas and Bonsing, Bert A and de Groot, Jan Willem B and Cirkel, Geert A and van Santvoort, Hjalmar C and Verpalen, Inez M and Molenaar, I Quintus and Wilmink, Johanna W and de Vos-Geelen, Judith and Daamen, Lois A and Engelbrecht, Marc R W and Homs, Marjolein Y V and Intven, Martijn P W and Stommel, Martijn W J and de Meijer, Vincent E and van der Geest, Lydia G and Besselink, Marc G and Dutch Pancreatic Cancer Group, Dutch Pancreatic Cancer Group},
  title = {Resectability stages of pancreatic cancer: nationwide reference},
  journal = {British Journal of Surgery},
  year = {2025},
  volume = {112},
  number = {7},
  doi = {10.1093/bjs/znaf120}
}
Kostenlos starten →